Pfizer (NYSE:PFE) received its first Chinese approval for obesity drug Severwin, opening access to a major new treatment ...

PFE stock is up 11% in 2026, but flat guidance, falling COVID sales and patent cliffs cloud its rebound story. Buy, sell or hold?

Those were in great demand at the beginning of the pandemic, and generated gobs of money for Pfizer. Demand has waned, though ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Eli Lilly(NYSE: LLY) is growing very quickly right now thanks to Mounjaro and Zepbound, its two GLP-1 drugs, the latter of ...

Pfizer steuert auf eine entscheidende Phase im Jahr 2026 zu. Morgen steht die nächste… Der Beitrag Pfizer Aktie: Viele Impulse erschien zuerst auf kapitalmarktexperten.de. Quelle kapitalmarktexperte ...

Pfizer Inc. (NYSE:PFE) is one of the best cheap stocks under $50 to buy right now. Pfizer Inc. (NYSE:PFE) and Astellas Pharma ...

Pfizer Inc. (NYSE:PFE) is among the 13 Most Undervalued S&P 500 Stocks to Invest In. On February 27, 2026, Pfizer Inc. (NYSE:PFE) and Astellas Pharma announced positive Phase 3 EV-304 results for ...

Amarin (NASDAQ: AMRN) is a drug company that is in a particularly precarious position. This fact is highlighted by the company's recent move to restructure its operations in an effort to cut costs.

Eli Lilly's market share in obesity drugs exceeds 60%, but further gains may be capped as competition escalates. Read why LLY ...

Teva is undergoing a major business transition, but dividend investors should check out this 6.3% yielding competitor instead ...

Es ist höchst ungewöhnlich, dass der CEO eines Pharmariesen öffentlich die wichtigste Regulierungsbehörde der… Der Beitrag Pfizer Aktie: Konflikt mit der FDA erschien zuerst auf kapitalmarktexperten ...